| | | | | | Note 15: | Earnings per Share |
Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | For the Three Months Ended June 30, | | For the Six Months Ended June 30, | | (In millions) | | 2025 | | 2024 | | 2025 | | 2024 | | Numerator: | | | | | | | | | | Net income attributable to Biogen Inc. | | $ | 634.8 | | | $ | 583.6 | | | $ | 875.3 | | | $ | 977.0 | | | Denominator: | | | | | | | | | | Weighted average number of common shares outstanding | | 146.5 | | | 145.6 | | | 146.3 | | | 145.4 | | | Effect of dilutive securities: | | | | | | | | | | | | | | | | | | | Time-vested restricted stock units | | 0.2 | | | 0.2 | | | 0.3 | | | 0.4 | | | | | | | | | | | | Performance stock units settled in stock | | — | | | 0.1 | | | 0.1 | | | 0.1 | | | Dilutive potential common shares | | 0.2 | | | 0.3 | | | 0.4 | | | 0.5 | | | Shares used in calculating diluted earnings per share | | 146.7 | | | 145.9 | | | 146.7 | | | 145.9 | |
Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.
|